Evotec AG (NASDAQ:EVO) Receives Consensus Rating of “Hold” from Brokerages

Evotec AG (NASDAQ:EVO) has received a consensus recommendation of “Hold” from the five research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $3.00.

EVO has been the subject of several recent research reports. HC Wainwright decreased their price objective on Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a report on Wednesday, July 15th. Wall Street Zen cut shares of Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. TD Cowen downgraded shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evotec in a report on Tuesday, July 21st.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of EVO. Apollon Wealth Management LLC acquired a new stake in Evotec in the first quarter valued at approximately $28,000. Marshall Wace LLP purchased a new stake in shares of Evotec during the 4th quarter valued at $40,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Evotec in the 1st quarter worth $44,000. BNP Paribas Financial Markets boosted its position in shares of Evotec by 62.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after buying an additional 9,289 shares during the last quarter. Institutional investors own 5.81% of the company’s stock.

Evotec Trading Down 3.0%

EVO opened at $1.96 on Friday. The business has a fifty day moving average of $2.38 and a 200 day moving average of $2.80. Evotec has a 52-week low of $1.89 and a 52-week high of $4.27. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.60 and a current ratio of 1.68.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.